# Research Program: Gene Expression and Regulation

> **NIH NIH P30** · WISTAR INSTITUTE · 2022 · $47,390

## Abstract

PROJECT SUMMARY – GENE EXPRESSION AND REGULATION
The Gene Expression and Regulation Program (GER) is comprised of eight laboratories that work together in
the areas of gene transcription and chromatin biology. The overarching goals of the Program match the long-
term vision of the Cancer Center to merge basic understanding of fundamental biological mechanisms with
translational identification of new, actionable therapeutic targets in cancer. To fulfill this goal, the GER Program
brings together complementary and synergistic scientific excellence in three flagship themes: (i) Transcription
and Chromatin Organization, (ii) Non-coding RNAs and Epigenetics, and (iii) Chromosomes and
Genome Dynamics. In addition, the GER Program is at the forefront of an interdisciplinary theme in Chemical
Biology of Novel Cancer Drug Targets, in line with the focus of the Cancer Center in early-stage academic
drug discovery. Progress during the last five years has been transformative. GER Program members continued
to lead their respective fields of investigation with high-impact publications in the top-tier literature,
strengthened their cancer focus and attracted new talents to build “critical mass” in flagship research themes.
The most far-reaching goals set forth in the last Cancer Center Support Grant (CCSG) renewal were also met.
GER Program members have now significantly expanded their intra- and inter-programmatic collaborations,
increased the utilization of Shared Resources, achieved important basic and translational milestones in the
ovarian cancer research continuum signature, and advanced innovative cancer therapeutics to the stage of
first-in-human testing. During the last CCSG budget cycle, GER Program members published 104 cancer-
related, discovery articles. Of these, 12.5% and 36.5% were the product of intra- or inter-programmatic
collaborations, respectively, compared to 7% and 19% of the previous CCSG budget cycle, bringing the total
collaborative publications of the Program from 23% in 2013 to more than 43% in 2018. Currently, GER
Program members receive $3.4 million in peer-reviewed, cancer-related funding (total funding, $4.9 million),
with $2.2 million from the NCI for a strong cancer focus of 64%. In addition, $2.2 million out of $3.4 million
(65%) of peer-reviewed funding is the product of internal or external collaborations. Accordingly, the Program
is home to two collaborative Program Project grants (P01 CA174439; P01 AG031862) and one multi-
institutional Specialized Program of Research Excellence in ovarian cancer (SPORE, P50 CA228991;
anticipated funding, 2018). In addition, the Program functions as a regional pole of collaborative research in
early-stage drug discovery, leading a Philadelphia Drug Discovery Forum that brings together expertise from
academic Institutions and the pharmaceutical and biotechnology industry. The GER Program is ideally poised
to continue on this exponential trajectory of research preeminence during the next CC...

## Key facts

- **NIH application ID:** 10360643
- **Project number:** 5P30CA010815-53
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** PAUL M. LIEBERMAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $47,390
- **Award type:** 5
- **Project period:** 1997-04-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10360643

## Citation

> US National Institutes of Health, RePORTER application 10360643, Research Program: Gene Expression and Regulation (5P30CA010815-53). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10360643. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*